Dr. Wayne Danter, MD, FRCPC – President and CEO

Dr. Wayne Danter is the President, Chief Executive Officer and a Director. Previously, he held the position of Chief Scientific Officer at COTI. Dr. Danter is the inventor of the CHEMSAS® process and one of the founders of COTI. He trained at the University of Western Ontario in Internal Medicine and Clinical Pharmacology. Prior to founding COTI, Dr. Danter was an Associate Professor of Medicine at the University of Western Ontario. His clinical focus, in addition to his teaching role, at the University was in General Cardiology, Cardiovascular Diseases associated with HIV a1d Cardiovascular Risk Management.

Dr. Danter's initial research focused on the medical application of Artificial Intelligence (AI) technologies to disease diagnosis and outcome prediction. The primary aspect of his research has focused on developing Hybrid AI models to pattern the relationship between molecular strudzure and biological activity. This research has resulted in a sophisticated process for decomposing complex molecules into critical elements that permit accurate molecular structure activity modeling (CHEMSAS). His research has been published in peer-reviewed publications and he has presented at numerous international meetings. Dr. Danter is a pioneer in the evolving interface between AI Technologies and pharmacotherapeutics. These AI technologies are anticipated to play a major role in 21st century drug development.

Mr. Gene Kelly - Chief Financial Officer

Mr. Gene Kelly is the Chief Financial Officer. He began his business career spending six years in public accounting with Clarkson Gordon. He brings to the company extensive experience from his 16-year career with the Cuddy Group of Companies, a large multinational multiplier turkey breeding company where he held various positions including: Director of Finance (Cuddy Farms), Vice President Commodity and Industry Affairs (Cuddy Foods), Vice President Strategic Implementations (Cuddy Farms) and Director of Quality Assurance and Process Improvement. Mr. Kelly is a graduate of the University of Windsor (HBComm).

Mr. Douglas Alexander, CA

Mr. Alexander is currently Lead Director and Chair of the Audit Committee of Saxon Financial Inc. (Saxon), an investment management firm listed on the TSX. He also is currently a Director of Hydrogenics Corporation, a global developer of clean energy solutions focused on commercializing hydrogen and fuel cell products trading on NASDAQ and the TSX. He is a member of their Human Resources and Compensation Committees as well as Chair of their Audit Committee. Prior to these directorships, Mr. Alexander served as Chief Financial Officer of various Canadian public companies for 15 years, the most recent being from 1999 to 2004 as executive Vice President and Chief Financial Officer of Trojan Technologies Inc., an international environmental technology company.

Mr. John Drake – Chairman

Mr. John Drake is the President and Founding Partner, Drake Goodwin Corporation in London, Ontario. Drake Goodwin Corporation is a London, Canada investment firm with diverse interests in financial services, real estate development and manufacturing. Drake Goodwin has realized substantial investment gains over the first 22 years of its history. Mr. Drake is Chairman of the DGM Bank & Trust Inc. of Barbados. Mr. Drake is also a director of Discovery Air Inc., a TSX Venture-listed company. Mr. Drake received his B.A. and LL.B. degrees from the University of Western Ontario.

Dr. Wayne Danter, MD, FRCPC – President and CEO

Dr. Wayne Danter is the President, Chief Executive Officer and a Director. Previously, he held the position of Chief Scientific Officer at COTI. Dr. Danter is the inventor of the CHEMSAS® process and one of the founders of COTI. He trained at the University of Western Ontario in Internal Medicine and Clinical Pharmacology. Prior to founding COTI, Dr. Danter was an Associate Professor of Medicine at the University of Western Ontario. His clinical focus, in addition to his teaching role, at the University was in General Cardiology, Cardiovascular Diseases associated with HIV a1d Cardiovascular Risk Management.

Dr. Danter's initial research focused on the medical application of Artificial Intelligence (AI) technologies to disease diagnosis and outcome prediction. The primary aspect of his research has focused on developing Hybrid AI models to pattern the relationship between molecular strudzure and biological activity. This research has resulted in a sophisticated process for decomposing complex molecules into critical elements that permit accurate molecular structure activity modeling (CHEMSAS). His research has been published in peer-reviewed publications and he has presented at numerous international meetings. Dr. Danter is a pioneer in the evolving interface between AI Technologies and pharmacotherapeutics. These AI technologies are anticipated to play a major role in 21st century drug development.

Mr. Bruno Maruzzo

Mr. Maruzzo is currently President of TecnhnoVenture Inc., a consulting company specializing in providing services to early stage technology companies. He has worked with a variety of public and private high technology companies in both the technology and life science sectors, where he held positions in a range of areas including business development, corporate development, investor relations, engineering management and general management. He has also worked in the venture capital field sourcing, assessing and making investments in early-stage, technology-based companies in Canada and the US. Prior to joining TecnhnoVenture Inc, Mr. Maruzzo worked for such companies as GeneNews, Empyrean Diagnostics, International Murex Technologies Corporation, and Visible Genetics Inc. Mr. Maruzzo holds a BASc in Electrical Engineering from the University of Waterloo, an MASC in Biomedical Engineering from the University of Toronto and an MBA from the University of Toronto.

Mr. Dave Sanderson, LLB

Mr. Sanderson is the President, CEO and a co-founder, of KFL Investment Management Inc. (KFL), an algorithmic hedge fund and proprietary trading firm based in Waterloo and London, Ontario. He is also an active private investor and co-founded Entertech Systems Inc. and Actual ID, companies that make biometric access, control and time and attendance technology and software. Mr. Sanderson is also a General Partner in a small venture fund that has investments in the medical device and security equipment industries. Prior to his role at KFL, Mr. Sanderson spent 15 years in the financial services industry with his most recent role as a Managing Director at BMO Nesbitt Burns where he managed one of the largest retail brokerage offices in Canada. Prior to this position, he worked in retail brokerage at TD Waterhouse and in distribution at AIM Trimark Investments.

Mr. Sanderson has a business degree from The Richard Ivey School of Business at Western University and a law degree from Queen’s University. He was called to the Ontario Bar in 1992 and practiced at Stikeman, Elliott in Toronto, Ontario for seven years as a corporate, commercial, and insolvency litigator. Mr. Sanderson has also been active in the community having served on the Board of Directors of London Health Sciences Centre from 2009-2012 and the Fowler Kennedy Sports Injury Clinic from 2009-2012.

Dr. Wayne Danter, MD, FRCPC – President and CEO

Dr. Wayne Danter is the President, Chief Executive Officer and a Director. Previously, he held the position of Chief Scientific Officer at COTI. Dr. Danter is the inventor of the CHEMSAS® process and one of the founders of COTI. He trained at the University of Western Ontario in Internal Medicine and Clinical Pharmacology. Prior to founding COTI, Dr. Danter was an Associate Professor of Medicine at the University of Western Ontario. His clinical focus, in addition to his teaching role, at the University was in General Cardiology, Cardiovascular Diseases associated with HIV a1d Cardiovascular Risk Management.

Dr. Danter's initial research focused on the medical application of Artificial Intelligence (AI) technologies to disease diagnosis and outcome prediction. The primary aspect of his research has focused on developing Hybrid AI models to pattern the relationship between molecular strudzure and biological activity. This research has resulted in a sophisticated process for decomposing complex molecules into critical elements that permit accurate molecular structure activity modeling (CHEMSAS). His research has been published in peer-reviewed publications and he has presented at numerous international meetings. Dr. Danter is a pioneer in the evolving interface between AI Technologies and pharmacotherapeutics. These AI technologies are anticipated to play a major role in 21st century drug development.

Dr. Henrik Hansen, Ph.D

Dr. Henrik Hansen is Director of Chemistry, Resverlogix Corp. and adjunct Assistant Professor, Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Calgary. He has extensive experience in medicinal chemistry, including lead identification, lead optimization and the analysis of screening data. He holds a Ph.D. in Chemistry from Lund University, Sweden and a Masters Degree in Chemistry from The Technical University of Denmark.

Dr. Jim Koropatnick, Ph.D

Dr. Jim Koropatnick is a Distinguished Oncology Scientist of the London Regional Cancer Program (at the London Health Sciences Centre), Director of the LRCP Cancer Research Laboratory Program of the LRCP, and a Full Professor in the UWO Department of Oncology with cross-appointments in the UWO Departments of Microbiology and Immunology, Physiology and Pharmacology, and Pathology.

Dr. Koropatnick obtained his Ph.D. in Genetics at UBC in 1980, studying DNA damage and repair, followed by a postdoctoral Alberta Heritage Medical Research Foundation Fellowship at the University of Calgary until 1984, working on cell stress events regulating gene transcription.

He is also the Chief Scientific Officer of Sarissa, Inc. and sits on the Scientific Advisory Boards of ID Laboratories, Inc., and Medvax Pharma, Inc. He is an Associate Editor of Toxicology and Applied Pharmacology.

Dr. Brigitte LeBreton, Ph.D

Dr. Lebreton has specialized in venture creation, strategic planning, scientific marketing and economic competitiveness for the life science industry. She is a Director of several innovative technology companies and acts as an expert advisor for financial institutions and international agencies.

Dr. Lebreton has held several executive positions in Canada as Executive Vice President with Procyon Biopharma Inc. (Virology and Oncology), President and CEO of Pharmacor Inc. (Drug discovery), Vice President Business Development for Nova Molecular (Neurology), Technology Transfer and Licensing Manager for Concordia University and President of the Canadian Institute of Biotechnology. She holds a Ph.D. in Science from Laval University, Canada, a Master of Science from the University of Aix-Marseille and a Bachelor's degree in Economics, France.

Dr. Mark Vincent, MB, MRCP, FRCPC

Dr. Vincent received his MD from the University of Cape Town in 1976, trained in Oncology at The Royal Marscen Hospital in London, England and came to Canada in 1987. He is a medical oncologist at the London Regional Cancer Program, a part of Cancer Care Ontario, where his activities include the management of lung and gastrointestinal cancer and laboratory research into the reversal of cytotoxic drug resistance by means of gene-directed therapy. His interests include the translation of basic research into the clinic, and the design and conduct of clinical trials in lung and colorectal cancer. Dr. Vincent has extensive experience as a consultant to Canadian and U.S. biotech and pharmaceutical companies. Dr. Vincent is also a member of several other biotechnology scientific advisory boards.

 
Critical Outcome Technologies Inc. home page
HOME COTI-2 PARTNERING PIPELINE CHEMSAS INVESTORS ABOUT US CONTACT

 

 

 

 

 




 

 


About Us

An Innovative Concept and a Passionate Team


Who We Are

Critical Outcome Technologies Inc. (COTI) believes that there must be a better way to get safe and effective new drug therapies to people in need on a more timely, cost effective and efficient manner.

Our business is disease-specific drug discovery, optimization and pre-clinical development using a specially developed series of computer models. COTI is focused on the discovery and pre-clinical development of small molecules for the treatment of serious diseases for which current therapy is either lacking or ineffective.


Our Mission

To be a world leader in drug discovery by providing our valued partners with targeted libraries of novel, optimized lead compounds.


Our Vision

To be instrumental in saving thousands of lives by enabling accelerated development of new effective treatment options.


Our Values

We value and strive to be innovative, resourceful, reliable, responsive and to work with high integrity.

Dr. Wayne Danter, MD, FRCPC
President and CEO
Mr. Gene Kelly
Chief Financial Officer
 
Mr. Douglas Alexander, CA
Mr. John Drake, Chairman
Dr. Wayne Danter, MD, FRCPC
President and CEO
Mr. Bruno Maruzzo
Mr. Dave Sanderson, LLB
 
Dr. Wayne Danter, MD, FRCPC
President and CEO
Dr. Henrik Hansen, Ph.D
Dr. Jim Koropatnick, Ph.D
Dr. Brigitte LeBreton, Ph.D
Dr. Mark Vincent, MB, MRCP, FRCPC
 
 
 
 
© 2014 Critical Outcome Technologies Inc. All rights reserved.